Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s ...

In a report released on December 19, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Toyota Motor Corp. (TM) and Vertex Pharmaceuticals Inc ... Competitive pressures, product ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

Cramer likes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and highlighted the company’s catalysts, including its non-opioid painkillers that are under development. “Oh, next, how about ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

VX-407 is under clinical development by Vertex Pharmaceuticals and currently ... data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center. Give your business an edge ...

The top 10 pharmaceutical stocks are released! Hengrui Medicine aims to hit a market value of 370 billion yuan ASH | BTK inhibitor development trends: Eli Lilly, BeiGene, and AZ announce clinical resu ...